Etaracizumab

伊瑞西珠单抗

Report date: 2022/08/29 20:00:24

Base Information

Drug NameEtaracizumab
Drug Alias NameAnti-alpha-v-beta-3 humanised monoclonal antibodyAnti-αvβ3 monoclonal antibodyVitaxin IIVitaxinAbegrin +[7] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionIntegrin alpha-V/beta-3 antagonists
TargetsIntegrin alpha-V/beta-3
Therapy Area/IndicationsSolid tumoursPsoriasisColorectal Neoplasms +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesFrance
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesMedimmune LlcEli Lilly And Company
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNational Cancer InstituteUniversity Of Wisconsin-MadisonMedimmune Llc
Active IndicationsN/A
Inactive IndicationsSolid tumoursPsoriasisColorectal Neoplasms +[8] 

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG